STOCK TITAN

Immunome Inc. (IMNM) grants CFO 94,500 options and 47,250 RSUs

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc. Chief Financial Officer Max Rosett received equity awards of 94,500 employee stock options and 47,250 restricted stock units on July 23, 2026.

The options have a $22.01 exercise price, expire July 22, 2036, and vest 25% on July 23, 2027 with the remainder vesting monthly. The RSUs vest 25% annually on each grant anniversary; after the RSU grant he held 101,287 common shares directly and 94,500 options.

Positive

  • None.

Negative

  • None.
Insider Rosett Max
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) F2 94,500 $0.00 $0.00
Grant/Award Common Stock F1 47,250 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 94,500 shares (Direct); Common Stock — 101,287 shares (Direct)
Footnotes (2)
  1. F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
  2. F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Stock options granted 94,500 shares Employee stock options granted to CFO on July 23, 2026
Option exercise price $22.01 per share Conversion or exercise price of employee stock options
Option expiration date July 22, 2036 Expiration date of granted employee stock options
RSUs granted 47,250 shares Restricted stock units tied to common stock granted July 23, 2026
Shares held after RSU grant 101,287 shares Total direct common stock holdings following RSU award
RSU annual vesting portion 25% Portion of RSUs that vest each year on grant-date anniversaries
Initial option vesting 25% Portion of options vesting on July 23, 2027
Subsequent option vesting 1/36 Fraction of remaining options vesting monthly after initial vest date
restricted stock units (RSUs) financial
"Represents the number of shares of Common Stock underlying restricted stock units (RSUs)."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
contingent right financial
"Each RSU represents the contingent right to receive one share of Common Stock."
vest financial
"25% of the RSUs will vest and settle into Common Stock annually."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
expiration date financial
"25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth of the remaining shares subject to the options shall vest every month thereafter."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Immunome Inc. (IMNM) grant to CFO Max Rosett?

Immunome granted CFO Max Rosett 94,500 employee stock options and 47,250 restricted stock units (RSUs) on July 23, 2026. The RSUs convert into common shares upon vesting, while the options allow future share purchases at a fixed exercise price.

What are the vesting terms of the RSUs granted to Immunome (IMNM) CFO?

The RSU grant to the CFO vests 25% each year on the anniversary of the July 23, 2026 grant date. Each RSU represents a contingent right to receive one Immunome common share upon settlement, subject to continued service through each vesting date.

What are the key terms of the stock options granted to Immunome (IMNM) CFO?

The CFO received 94,500 stock options with a $22.01 exercise price, expiring July 22, 2036. 25% of the options vest on July 23, 2027, and one‑thirty‑sixth of the remaining options vests each month thereafter, subject to continued service.

How many Immunome (IMNM) shares does the CFO hold after these grants?

Following the RSU grant, the CFO directly held 101,287 shares of Immunome common stock and 94,500 stock options. The RSUs themselves are not common shares until they vest and settle, but they are linked one-for-one to common stock.

Were the Immunome (IMNM) CFO awards reported under a Rule 10b5-1 plan?

The awards were not reported as made under a Rule 10b5-1 trading plan. The filing’s Rule 10b5-1 checkbox was left unchecked, and no footnote indicates they were granted pursuant to a pre-arranged trading plan.

Do the Immunome (IMNM) RSUs immediately provide common shares to the CFO?

No. Each RSU represents a contingent right to receive one share of common stock upon settlement. Shares are delivered only as the RSUs vest and settle, subject to the CFO’s continuous service through each vesting date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rosett Max

(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100

(Street)
BOTHELL WASHINGTON 98011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/23/2026A47,250(1)A$0101,287D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$22.0107/23/2026A94,500 (2)07/22/2036Common Stock94,500$094,500D
Explanation of Responses:
1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
/s/ Sandra Stoneman, Attorney-in-Fact07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)